Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Post-transcriptional regulation by cytosine-5 methylation of RNA

  • García-Vílchez, Raquel
  • Sevilla Hernández, Ana
  • Blanco, Sandra
The recent advent of high-throughput sequencing technologies coupled with RNA modifications detection methods has allowed the detection of RNA modifications at single nucleotide resolution giving a more comprehensive landscape of post-transcriptional gene regulation pathways. In this review, we focus on the occurrence of 5-methylcytosine (m5C) in the transcriptome. We summarise the main findings of the molecular role in post-transcriptional regulation that governs m5C deposition in RNAs. Functionally, m5C deposition can regulate several cellular and physiological processes including development, differentiation and survival to stress stimuli. Despite many aspects concerning m5C deposition in RNA, such as position or sequence context and the fact that many readers and erasers still remain elusive, the overall recent findings indicate that RNA cytosine methylation is a powerful mechanism to post-transcriptionally regulate physiological processes. In addition, mutations in RNA cytosine-5 methyltransferases are associated to pathological processes ranging from neurological syndromes to cancer., R.G-V is a PhD student supported by the Spanish Ministry of Economy and Innovation (MINECO) PhD fellowship (BES-2017-080530). A. S. is a recipient of a Ramón y Cajal contract (RYC-2016-19962). S.B. is a Research Scientist (Científico Titular) of the Spanish Research Council (CSIC) and has been supported by a Ramón y Cajal fellowship for junior investigators (RYC-2014-16550). We acknowledge funding from the Spanish Ministry of Economy and Innovation (MINECO) and Agencia Estatal de Investigación (AEI) and co-financed by the European Development Regional Fund (FEDER) under grant no. SAF2016-78667-R. We thank the Spanish Ministry if Economy and Innovation for the Ochoa Excellence Accreditation of CIC bioGUNE (SEV-2016-0644). We gratefully thank Peter Humphreys for his editorial contribution. S.B.'s institution is supported by the Programa de Apoyo a Planes Estratégicos de Investigación de Estructuras de Investigación de Excelencia cofunded by the Castilla–León autonomous government and the European Regional Development Fund (CLC–2017–01)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

N7-methylguanosine methylation of tRNAs regulates survival to stress in cancer

  • García-Vílchez, Raquel
  • Añazco-Guenkova, Ana M.
  • López, Judith
  • Dietmann, Sabine
  • Tomé, Mercedes
  • Jimeno, Sonia
  • Azkargorta, Mikel
  • Elortza, Félix
  • Bárcena, Laura
  • Gonzalez-Lopez, Monika
  • Aransay, Ana M.
  • Sánchez-Martín, Manuel A.
  • Huertas Sánchez, Pablo
  • Durán, Raúl V.
  • Blanco, Sandra
Tumour progression and therapy tolerance are highly regulated and complex processes largely dependent on the plasticity of cancer cells and their capacity to respond to stress. The higher plasticity of cancer cells highlights the need for identifying targetable molecular pathways that challenge cancer cell survival. Here, we show that N7-guanosine methylation (m7G) of tRNAs, mediated by METTL1, regulates survival to stress conditions in cancer cells. Mechanistically, we find that m7G in tRNAs protects them from stress-induced cleavage and processing into 5' tRNA fragments. Our analyses reveal that the loss of tRNA m7G methylation activates stress response pathways, sensitising cancer cells to stress. Furthermore, we find that the loss of METTL1 reduces tumour growth and increases cytotoxic stress in vivo. Our study uncovers the role of m7G methylation of tRNAs in stress responses and highlights the potential of targeting METTL1 to sensitise cancer cells to chemotherapy., This work was funded by the Spanish Ministry of Science and Innovation MICINN/AEI/ 10.13039/501100011033 and by “ERDF A way of making Europe”, by the “European Union” (SAF2016-78667-R and PID2019-111692RB-I00), MINECO (RYC-2014-16550), AECC (LABAE19040BLAN), and Consejería de Educación de la Junta de Castilla y León (CSI264P20) to S.B. R.G-V. was supported by MICINN/AEI /10.13039/501100011033 and by “ESF Investing in your future” (BES-2017-080530). A.M.A-G. was supported by USAL-Santander PhD fellowship. J.L. was supported by AECC (PRDSA19002LÓPE) and MIU (FPU19/01190). The Instituto de Biología Molecular y Celular del Cancer is supported by the Programa de Apoyo a Planes Estratégicos de Investigación de Estructuras de Investigación de Excelencia co-financed by the Castilla–León autonomous government and the European Regional Development Fund (CLC–2017–01). R.V.D. work was supported by Agencia Estatal de Investigación/European Regional Development Fund, European Union (PGC2018-096244-B-I00, Ministry of Science and Innovation of Spain, Spanish National Research Council-CSIC (2021AEP005). The authors wish to thank the donors, and the Biobank Hospital Universitario Puerta de Hierro Majadahonda (HUPHM)/Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana (IDIPHISA) (PT17/0015/0020 in the Spanish National Biobanks Network) for the human specimens used in this study. The authors wish to thank all the core facilities that support the work., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

METTL1 promotes tumorigenesis through tRNA-derived fragment biogenesis in prostate cancer

  • García-Vílchez, Raquel
  • Añazco-Guenkova, Ana M.
  • Dietmann, Sabine
  • López, Judith
  • Morón-Calvente, Virginia
  • D'Ambrosi, Silvia
  • Nombela, Paz
  • Zamacola, Kepa
  • Mendizábal, Isabel
  • García-Longarte, Saioa
  • Zabala-Letona, Amaia
  • Astobiza, Ianire
  • Fernández, Sonia
  • Paniagua, Alejandro
  • Miguel-López, Borja
  • Marchand, Virginie
  • Alonso-López, Diego
  • Merkel, Angelika
  • García-Tuñón, Ignacio
  • Ugalde-Olano, Aitziber
  • Loizaga-Iriarte, Ana
  • Lacasa-Viscasillas, Isabel
  • Unda, Miguel
  • Azkargorta, Mikel
  • Elortza, Félix
  • Bárcena, Laura
  • Gonzalez-Lopez, Monika
  • Aransay, Ana M.
  • Di Domenico, Tomás
  • Sánchez-Martín, Manuel A.
  • De Las Rivas, Javier
  • Guil, Sònia
  • Motorin, Yuri
  • Helm, Mark
  • Pandolfi, Pier Paolo
  • Carracedo, Arkaitz
  • Blanco, Sandra
Newly growing evidence highlights the essential role that epitranscriptomic marks play in the development of many cancers; however, little is known about the role and implications of altered epitranscriptome deposition in prostate cancer. Here, we show that the transfer RNA N7-methylguanosine (m7G) transferase METTL1 is highly expressed in primary and advanced prostate tumours. Mechanistically, we find that METTL1 depletion causes the loss of m7G tRNA methylation and promotes the biogenesis of a novel class of small non-coding RNAs derived from 5'tRNA fragments. 5'tRNA-derived small RNAs steer translation control to favour the synthesis of key regulators of tumour growth suppression, interferon pathway, and immune effectors. Knockdown of Mettl1 in prostate cancer preclinical models increases intratumoural infiltration of pro-inflammatory immune cells and enhances responses to immunotherapy. Collectively, our findings reveal a therapeutically actionable role of METTL1-directed m7G tRNA methylation in cancer cell translation control and tumour biology., This work was funded by the Spanish Ministry of Science and Innovation MICINN/AEI/1013039/501100011033 and by “ERDF A way of making Europe”, by the “European Union” (SAF2016-78667-R and PID2019-111692RB-I00), MINECO (RYC-2014-16550), AECC (LABAE19040BLAN), Proteored-ISCIII, and Consejería de Educación de la Junta de Castilla y León (CSI264P20). R.G-V. was supported by MICINN/AEI/1013039/501100011033 and by “ESF Investing in your future” (BES-2017-080530). A.M.A-G. was supported by the USAL-Santander PhD fellowship. J.L-L. was supported by the AECC (PRDSA19002LÓPE) and MIU(FPU19/01190). B.M.L. was supported by Junta de Castilla y León ‐ Fondo Social Europeo (ESF). I.M. was supported by the Cris contra el cáncer grant PR_TPD_2020-19. The work of A. Carracedo is supported by the MICINN (PID2019-108787RB-I00 (FEDER/EU); Excellence Networks RED2018-102769-T), the AECC (GCTRA18006CARR), La Caixa Foundation (ID 100010434), under the agreement LCF/PR/HR17/ and the European Research Council (Consolidator Grant 819242). CIBERONC was co-funded by FEDER funds and ISCIII. The Instituto de Biología Molecular y Celular del Cancer is supported by the Programa de Apoyo a Planes Estratégicos de Investigación de Estructuras de Investigación de Excelencia co-financed by the Castilla–León autonomous government and the European Regional Development Fund (CLC–2017–01)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Global and single-nucleotide resolution detection of 7-methylguanosine in RNA

  • D’Ambrosia, Silvia
  • García-Vílchez, Raquel
  • Kedrac, Darek
  • Vitalie, Patrice
  • Macias-Cámara, Nuria
  • Bárcena, Laura
  • Gonzalez-Lopez, Monika
  • Aransay, Ana M.
  • Dietmann, Sabine
  • Hurtado, Antonio
  • Blanco, Sandra
RNA modifications, including N-7-methylguanosine (m7G), are pivotal in governing RNA stability and gene expression regulation. The accurate detection of internal m7G modifications is of paramount significance, given recent associations between altered m7G deposition and elevated expression of the methyltransferase METTL1 in various human cancers. The development of robust m7G detection techniques has posed a significant challenge in the field of epitranscriptomics. In this study, we introduce two methodologies for the global and accurate identification of m7G modifications in human RNA. We introduce borohydride reduction sequencing (Bo-Seq), which provides base resolution mapping of m7G modifications. Bo-Seq achieves exceptional performance through the optimization of RNA depurination and scission, involving the strategic use of high concentrations of NaBH4, neutral pH and the addition of 7-methylguanosine monophosphate (m7GMP) during the reducing reaction. Notably, compared to NaBH4-based methods, Bo-Seq enhances the m7G detection performance, and simplifies the detection process, eliminating the necessity for intricate chemical steps and reducing the protocol duration. In addition, we present an antibody-based approach, which enables the assessment of m7G relative levels across RNA molecules and biological samples, however it should be used with caution due to limitations associated with variations in antibody quality between batches. In summary, our novel approaches address the pressing need for reliable and accessible methods to detect RNA m7G methylation in human cells. These advancements hold the potential to catalyse future investigations in the critical field of epitranscriptomics, shedding light on the complex regulatory roles of m7G in gene expression and its implications in cancer biology., This work was funded by the Spanish Ministry of Science and Innovation MCIN/AEI/10.13039/501100011033 and by “ERDF A way of making Europe”, by the “European Union” [SAF2016-78667-R, PID2019-111692RB-I00, and PID2022-139598OB-I00]. In addition, we acknowledge funding from The Scientific Foundation AECC [LABAE19040BLAN], and the University of Salamanca and Fundación Memoria de Samuel Solorzano Barruso [FS/21-2018, FS/25-2019, FS/36-2020] and Consejería de Educación de la Junta de Castilla y León [CSI264P20] to S.B. S.B. was supported by Ramón y Cajal program from Spanish Ministry of Economy and Innovation [MINECO] [RYC2014-16550]. R.G-V. was supported by a predoctoral fellowship funded by MCIN/AEI/10.13039/501100011033 and by “ESF Investing in your future” (BES-2017-080530). The Instituto de Biología Molecular y Celular del Cancer is supported by the Programa de Apoyo a Planes Estratégicos de Investigación de Estructuras de Investigación de Excelencia co-financed by the Castilla–León autonomous government and the European Regional Development Fund [CLC–2017–01]. S.B., R.G-V., A.H. and D.K. belong to the Spanish National Research Council (CSIC)’s Cancer Hub., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

METTL1 promotes tumorigenesis through tRNA-derived fragment biogenesis in prostate cancer

  • García-Vílchez, Raquel
  • Añazco-Guenkova, Ana M.
  • Dietmann, Sabine
  • López, Judith
  • Morón-Calvente, Virginia
  • D'Ambrosi, Silvia
  • Nombela, Paz
  • Zamacola, Kepa
  • Mendizabal, Isabel
  • García-Longarte, Saioa
  • Zabala-Letona, Amaia
  • Astobiza, Ianire|||0000-0002-7142-7066
  • Fernández, Sonia
  • Paniagua, Alejandro|||0000-0002-7794-8321
  • Miguel-López, Borja
  • Marchand, Virginie
  • Alonso-López, Diego
  • Merkel, Angelika|||0000-0001-5164-6803
  • García-Tuñón, Ignacio
  • Ugalde-Olano, Aitziber
  • Loizaga-Iriarte, Ana
  • Lacasa-Viscasillas, Isabel
  • Unda, Miguel
  • Azkargorta, Mikel
  • Elortza, Felix|||0000-0001-8839-5438
  • Barcena, Laura
  • Gonzalez-Lopez, Monika
  • Aransay, Ana M.|||0000-0002-8271-612X
  • Di Domenico, Tomás
  • Sánchez-Martín, Manuel A.|||0000-0001-8370-1336
  • De Las Rivas, Javier
  • Guil, Sonia|||0000-0002-2257-3331
  • Motorin, Yuri
  • Helm, Mark|||0000-0002-0154-0928
  • Pandolfi, Pier Paolo
  • Carracedo, Arkaitz|||0000-0001-5957-1260
  • Blanco, Sandra
Newly growing evidence highlights the essential role that epitranscriptomic marks play in the development of many cancers; however, little is known about the role and implications of altered epitranscriptome deposition in prostate cancer. Here, we show that the transfer RNA N7-methylguanosine (m7G) transferase METTL1 is highly expressed in primary and advanced prostate tumours. Mechanistically, we find that METTL1 depletion causes the loss of m7G tRNA methylation and promotes the biogenesis of a novel class of small non-coding RNAs derived from 5'tRNA fragments. 5'tRNA-derived small RNAs steer translation control to favour the synthesis of key regulators of tumour growth suppression, interferon pathway, and immune effectors. Knockdown of Mettl1 in prostate cancer preclinical models increases intratumoural infiltration of pro-inflammatory immune cells and enhances responses to immunotherapy. Collectively, our findings reveal a therapeutically actionable role of METTL1-directed m7G tRNA methylation in cancer cell translation control and tumour biology.